康泰生物：吸附无细胞百白破（组分）联合疫苗临床试验申请获受理

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd., has received an acceptance notice from the National Medical Products Administration for its clinical trial application of an acellular DTP (diphtheria, tetanus, and pertussis) combined vaccine for adults, adolescents, and children [1] Group 1 - The vaccine is intended for the prevention of whooping cough, diphtheria, and tetanus [1] - Currently, there are no similar products approved for sale in the domestic market [1]